Key result
Remimazolam did not significantly reduce the incidence of intraoperative hypotension compared to sevoflurane (85.1% vs. 91.5%, p=0.138) in adult patients undergoing noncardiac surgery.
Why the study?
The effects of remimazolam versus sevoflurane on intraoperative hemodynamics including intraoperative hypotension in noncardiac surgery were compared due to limited data.
Does remimazolam reduce intraoperative hypotension compared to sevoflurane in adult patients undergoing noncardiac surgery?
Observational (n=282)
No
Does remimazolam reduce intraoperative hypotension compared to sevoflurane in adult patients undergoing noncardiac surgery?
Absolute Event Rate: 85.1% vs 91.5%
p-value: p=0.138
Remimazolam for maintenance anesthesia in noncardiac surgery does not significantly reduce the incidence of intraoperative hypotension compared to sevoflurane, but it may reduce the cumulative duration of hypotension and need for vasopressors.
Should not yet change practice for hypotension prevention in noncardiac surgery; hypothesis-generating for effects on duration or vasopressor needs.
BACKGROUND: This study compared the effects of remimazolam and sevoflurane on intraoperative hemodynamics including intraoperative hypotension (IOH). RESULTS: This study involved adult patients undergoing noncardiac surgery using remimazolam (Group R) or sevoflurane (Group S) for maintenance anesthesia, and invasive arterial pressure measurements, from September 2020 to March 2023 at our hospital. IOH was defined as a mean blood pressure < 65 mmHg occurring for a cumulative duration of at least 10 min. A 1:1 propensity score-matching method was used. The primary endpoint was the occurrence of IOH, and the secondary endpoints were the cumulative hypotensive time, incidence of vasopressor use, and dose of vasopressor used (ephedrine, phenylephrine, dopamine, and noradrenaline). Group R comprised 169 patients, Group S comprised 393 patients, and a matched cohort of 141 patients was created by propensity score matching. There was no significant difference in the incidence of IOH between the two groups (85.1% in Group R vs. 91.5% in Group S, p = 0.138). Patients in Group R had a significantly lower cumulative hypotension duration (55 [18-119] vs. 83 [39-144] min, p = 0.005), vasopressor use (81.6% vs. 91.5%, p = 0.023), and dose of ephedrine (4 [0-8] vs. 12 [4-20] mg, p < 0.001) than those in Group S. There were no significant differences in the doses of other vasopressors between groups. CONCLUSIONS: Compared with sevoflurane, the maintenance of anesthesia with remimazolam was not associated with a decreased incidence of IOH; however, it reduced the cumulative hypotension time, incidence of vasopressor use, and dose of ephedrine.
No takes yet. Share an insight, caveat, or question.
Katsuragawa et al. (2023) conducted an observational in Noncardiac surgery under general anesthesia (n=282). Remimazolam vs. Sevoflurane was evaluated on Incidence of intraoperative hypotension (mean blood pressure < 65 mmHg for a cumulative duration of ≥ 10 min) (p=0.138). Remimazolam did not significantly reduce the incidence of intraoperative hypotension compared to sevoflurane (85.1% vs. 91.5%, p=0.138) in adult patients undergoing noncardiac surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: